Fosun Pharma subsidiary, Henlius, to adopt equity incentive plan

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced that its holding subsidiary, Shanghai Henlius Biotech, plans to adopt an equity incentive plan comprising both share option and restricted share unit schemes. Under these schemes, Henlius plans to grant options for up to 8% of its total share capital, inclusive of treasury shares. If fully implemented via the issuance of new H-shares, Fosun Pharma’s equity stake in Henlius could decrease to approximately 58.73% from the current 63.43%, whilst still maintaining Henlius as a consolidated subsidiary.